What You Should Know:
- Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million investment from Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures.
- As a spinoff from Intermountain Health, Culmination Bio maintains exclusive rights to a physical library and cloud-based data lake covering over 40 years of de-identified patient electronic health records and biospecimen data.
Data Driven Insights Enabled by Merck and Amgen Fundings
As the most extensive repository of its kind, this data lake empowers biopharmaceutical companies by providing crucial insights necessary for advancing diagnostic and therapeutic development. The recent funding secured by Culmination Bio will enable the further enhancement of its exclusive Intelligence Platform and the expansion of its commercial growth.
Presently, there is no streamlined method for bringing a drug or diagnostic to market, with the process often extending over a decade and incurring billions of dollars in costs for regulatory approval. The challenge originates from the time-consuming task of acquiring longitudinal biological and clinical patient data, a process that takes life sciences and biotech companies months to complete.
Culmination Bio addresses this hurdle by offering a continually expanding library of over five million de-identified patient samples and clinical data spanning several decades. Biotech and life sciences companies collaborate with Culmination Bio to swiftly access retrospective patient data and efficiently reach thousands of prospective patients for their studies.
“With support from our investors, Culmination Bio is raising the bar for healthcare innovation,” said Lincoln Nadauld, MD, Ph.D., president and CEO of Culmination Bio. “On top of our existing longitudinal patient data, we are adding over 300,000 biospecimens to our data lake each year. Because of this, we have the ability to quickly identify unique patient cohorts from our vast data lake that can speed up critical research, leading to novel discoveries..”